| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| ln Vitro |
β-amyloid proteins (1-40) and (1-42) are major components of amyloid in senile plaques and are also physiological peptides present in the brain, cerebrospinal fluid (CSF), and plasma. The levels of β-amyloid proteins (1-40) and (1-42) in CSF exhibit a U-shaped change during normal aging [1]. Further aggregation of β-amyloid protein (1-40): 1. Solid Aβ peptides were dissolved in cold hexafluoroisopropanol (HFIP). The peptides were incubated at room temperature for at least 1 hour to monomerize and randomize their structure. 2. HFIP was removed by evaporation, and the resulting peptides were stored in thin film form at -20 or -80°C. 3. The resulting film was dissolved in 5 mM anhydrous DMSO, then diluted to an appropriate concentration using a vortex mixer, and buffer (serum- and phenol red-free medium) was added. 4. The solution was then allowed to stand at 4-8°C for 48 hours. The sample was then centrifuged at 14000 g for 10 minutes at 4-8°C; soluble oligomers were present in the supernatant. The supernatant was diluted 10-200 times for use in experiments. The specific method depends on the subsequent application.
|
|---|---|
| ln Vivo |
β-amyloid protein (1-40) can be used to construct an Alzheimer's disease model in animal models. Induction of Alzheimer's disease [2] Background β-amyloid protein (1-40) induces Alzheimer's disease by accumulating in the brain and having neurotoxicity. Specific modeling method Rats: Wistar • Male • 280-320 g Dosing: 0, 3, 30, 300 pmol • Connect the cannula to a modified micro osmotic pump for infusion • 2 weeks Note: (1) Dissolve β-amyloid protein (1-40) in 35% acetonitrile/0.1% trifluoroacetic acid (TFA) solution. (2) In each group of 7 rats, the cannula was inserted into the left ventricle on day 1. The water maze test was performed on days 9-13 after the start of infusion. After the behavioral experiment, four rats were taken from each group and decapitated for ChAT activity determination. Three more rats were taken for histochemical studies. (3) In the histochemical studies, after anesthesia, the rats were first perfused with cold physiological saline, then with 4% paraformaldehyde and 0.1 M sodium phosphate buffer, and then fixed by perfusion via the aorta. The brain tissue was removed and fixed in the same fixative for 12 hours. The frozen brain tissue was cut into 20 μm thick sections using a cryostat and the periventricular region was collected. Model indicators: Molecular changes: Decreased acetyltransferase (ChAT) activity in the frontal cortex and hippocampus, and cholinergic neuron dysfunction. Tissue structure changes: β-amyloid protein accumulated in the hippocampus and cerebral cortex. Phenotypic observation: Memory impairment occurred.
|
| References |
| Molecular Formula |
C194H295N53O58S.C2HF3O2
|
|---|---|
| Molecular Weight |
4443.84
|
| Related CAS # |
β-Amyloid (1-40), HFIP-treated TFA; β-Amyloid-15N (1-40) TFA
|
| Sequence |
Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-ValDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV
|
| SequenceShortening |
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV
|
| Appearance |
White to off-white solid
|
| Synonyms |
Amyloid β-Peptide (1-40) (human) TFA; Aβ40 (human) TFA; Aβ(1-40) (human) TFA
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). 请将本产品存放在密封且受保护的环境中（例如氮气下），避免暴露在潮湿和光照下。 (2). 该产品溶液不稳定，请使用新鲜配制的工作溶液以获得最佳效果。 |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~22.50 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.2250 mL | 1.1252 mL | 2.2503 mL | |
| 5 mM | 0.0450 mL | 0.2250 mL | 0.4501 mL | |
| 10 mM | 0.0225 mL | 0.1125 mL | 0.2250 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
